Literature DB >> 2909236

Esophageal stethoscope. Another possible cause of vocal cord paralysis.

M Friedman1, D M Toriumi.   

Abstract

Hoarseness after endotracheal intubation can result from compression of the anterior branch of the recurrent laryngeal nerve as it passes behind the thyroid cartilage to innervate the lateral cricoarytenoid muscle. This usually occurs when the cuff of the endotracheal tube lies in the larynx instead of the trachea. When a nasogastric tube is positioned in the midline, resultant postcricoid inflammation can result in vocal cord immobility. This may result from neuropraxia of the posterior branch of the recurrent laryngeal nerve that innervates the posterior cricoarytenoid and interarytenoid muscles, or inflammatory spasm of the interarytenoid muscles themselves. We present a case of vocal cord paralysis after general anesthesia that may have been caused by an esophageal stethoscope. The mechanism for vocal cord immobility could be similar to that of a midline nasogastric tube with resultant postcricoid inflammation. We describe measures that can be taken to prevent vocal cord paralysis after intubation of the larynx or esophagus.

Entities:  

Mesh:

Year:  1989        PMID: 2909236     DOI: 10.1001/archotol.1989.01860250097035

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  3 in total

1.  Vocal cord paralysis associated with difficult gastric tube insertion.

Authors:  T Ibuki; N Ando; Y Tanaka
Journal:  Can J Anaesth       Date:  1994-05       Impact factor: 5.063

2.  The hoarse patient: asking the right questions.

Authors:  Ji-Eon Kim; Barry Rasgon
Journal:  Perm J       Date:  2010

3.  Bilateral vocal cord paralysis after endoscopic placement of fully covered self-expandable metal stent for palliative treatment of malignant proximal esophageal obstruction: two case reports.

Authors:  Y Chiche; G Beltramo; T Degand; A Drouillard; C Foignot; N Baudouin; P Bonniaud; M Georges
Journal:  BMC Gastroenterol       Date:  2020-05-14       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.